🎉 Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application

Psychedelic Breakthrough

By Rachel Dundas, Registered Psychologist Certified Trauma Practitioner


The Role of Psychedelics in Therapeutic Breakthroughs

One of the main goals of psychotherapy is to guide patients toward therapeutic
breakthroughs – defined as a significant, sometimes sudden, step forward or important realization. Oftentimes, in therapy, breakthroughs come after long, unproductive plateaus. Such realizations must come from the client themselves; while the therapist’s role involves guiding the client, honest and complete acceptance and understanding must come from within. Breakthroughs are important because they are a critical step for patients to make meaningful life changes.

In conventional psychotherapeutic models, breakthroughs often come after months or years of therapy; one of the remarkable aspects of psychedelics is that breakthroughs can come after just one session, and can have long-lasting effects, allowing for patients to progress further and faster than via conventional practices. There are two important mechanisms by which psychedelics produce these rapid and sustained effects: the mystical experience and changes in neurochemistry. Insights largely surface as a result of the intense and vivid mystical experience. Modifications in neurochemistry result in changes in cognitive patterns, allowing for these insights to be adopted into one’s life for long-term effects.

The mystical experience is composed of both introvertive and extrovertive
phenomenological content. Introvertive content encompasses a sense of unity or
oneness, the transcendence of time and space, a deeply felt positive mood, a sense of awesomeness, reverence and wonder, meaningfulness of psychological or philosophical insight, and ineffability, while extrovertive phenomenological content is that of sensory-perceptual, somatosensory, or introspective mystical content. The ‘entity encounter experience’ is a particularly interesting extrovertive feature whereby people meet autonomous entities described as ‘beings,’ ‘spirits,’ ‘angels,’ etc., who possess intelligence and agency, and are felt to be powerful, wise, and loving. Emotions such as joy, trust, and love are often felt with such encounters.

Studying the mystical experience can be challenging due to the subjective and ineffable nature of the experience. Further, operationally defining the mystical experience carries the risk of depersonalizing individual experiences. While the questionnaires that are used in research to operationalize the mystical experience (e.g., the Mystical Experience Questionnaire – MEQ-30) are necessary in order to standardize comparisons across studies, it is important to avoid reducing the mystical experience to a simple questionnaire, and to not dismiss the individual stories of transformation and healing that occur as a result. These stories give meaning to both the mystical experience and to psychedelic medicine. Breakthroughs that once seemed unlikely or impossible are able to emerge as a result of psychedelic use, and it does the medicine a disservice by reducing such ground-breaking experiences to a questionnaire that does not encapsulate the individual experience.

There are changes in neuropathways that accompany the mystical experience. The Default Mode Network (DMN) is one important network that is involved in the long-term effects of the psychedelic experience. The DMN consists of neural pathways that are activated during stimulus-independent thought – thoughts that occur when the brain is ‘at rest’ or when the mind is wandering, and are not triggered by external stimuli (vs. stimulus-dependent or task-oriented thinking). Such thoughts have a general theme of ‘the self,’ including thoughts pertaining to self-awareness, self-recognition, self-control, a sense of agency, theory of mind, and self-identity, to name a few. Psychedelics reset the DMN by dampening its activity, allowing for individuals to direct their attention away from internal emotional and cognitive states, and embrace a different, more holistic pattern of thinking, by which breakthroughs are able to emerge. In addition, while conventional anti-depressant medications decrease the fear response via inhibition of the amygdalae, psychedelics take this a step further and increase activation in response to positive emotional stimuli.

Rapid and sustained breakthroughs are important for several reasons. First, the rapid breakthroughs that result from psychedelic-assisted therapy tend to be more intense than those experienced in regular psychotherapy; although potentially overwhelming, with proper psychotherapy, such intense breakthroughs have the potential to result in more significant cognitive and behavioural changes. Second, in terms of quality of life for the patient, the quick onset and long-lasting relief that psychedelics provide is the ideal scenario for patients – such a scenario is not typically seen with conventional anti-depressant medications, often resulting in patients struggling for months or even years. Third, for many patients, time is of the essence. Psychedelics have been shown to be effective in relieving end-of-life anxiety experienced by palliative care patients. Palliative care patients do not have the luxury of waiting months or years to test different anti-depressants to find the most effective one for them. Additionally, it is often the content of the mystical experience that provides therapeutic insight.

More News and Media:

Health Canada Provides a No Objection Letter for ATMA’s N500 Phase II Clinical Trial Application, Paving the Way for the Largest Psilocybin Trial to Date

This trial will assess psilocybin efficacy in frontline healthcare professionals suffering from COVID-19-related mental wellness challenges. CALGARY, AB, Sept. 14, 2022 /CNW/ – ATMA Journey Centers Inc. (“ATMA”), an Alberta-based company focused on the international delivery of innovative psychedelic-assisted therapy solutions, announced today that it has received approval from Health Canada to move forward with its N500 Phase II psilocybin

ATMA Journey Centers observes positive outcomes from a Phase I clinical trial of psilocybin in healthy participants

Fourteen healthy subjects completed an experiential session after receiving 25 mg psilocybin  – Results of this phase I study will inform the design of Phase II study in frontline healthcare workers, examining the efficacy of psilocybin for Covid-related stress. Calgary, September 7, 2022 — ATMA Journey Centers (the “Company”), a company providing therapist training and support, has

Thank You Letter

Dear mental healthcare professionals, A deep heart-felt thank you is warranted to you for bearing the weight of the current mental health crisis, especially during these last tough couple of years. I have heard from many of your peers regarding the increased pressure, overburdening workloads, and feelings of burnout that have become an all too frequent occurrence.

Breaking Through the Stigma

By David Harder, ATMA co-founder and co-CEO I met with a gentleman – a pastor of sorts – from my former religious life. We sat down to enjoy a pint and a burger at a local watering hole. It had been many years since we had last spoken, simply due to the chaos of life,

How To Change Your Mind

Upon the release of his book How to Change Your Mind, Michael Pollan sparked a major shift in the mindset of numerous therapists and medical professionals, as well as the general public. At the time of its publication in the spring of 2019, discussions surrounding psychedelics were happening, but in small, hushed groups of underground

Clinical Trials and Psychedelics

Clinical trials are the standard way to evaluate the safety and efficacy of new drugs (including psychedelic drugs) for medical use. Clinical trials also serve to test novel treatment options, explore ways to improve quality of life for people living with illnesses or diseases, and assess whether a new drug or treatment has fewer side

Psilocybin-assisted Therapy: The Safe and Effective Alternative

Psilocybin-assisted therapy is becoming an increasingly widespread treatment for various mental health conditions. However, many healthcare professionals may be hesitant to use this type of treatment with their patients because of the misconception that psychedelics are dangerous and unsafe. This blog post will share evidence of the safety of psilocybin as an effective treatment option

Magic Mushroom - ATMA

Magic Mushrooms (Psilocybin) and End-of-life

End-of-life distress has been an ongoing focus for psilocybin clinical trials, as psilocybin has the potential to offer relief for existential distress when other forms of treatment fail. Health Canada has granted access to psilocybin through the Section 56 Exemption program, which is a patient led application requesting access to psilocybin. These exemptions are reviewed

Scroll to Top